Meng Jiao Jiang

I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China.

CMAB BioPharma (Suzhou) Inc. develops and manufactures biological products. Its services include process development, GMP manufacturing, aseptic drug and quality development. The company was founded by Qibin Liang in June 2017 and is headquartered in Suzhou, China.

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.

Part of ARC China Holdings Ltd., ARC China, Inc. is a financial investment firm based in Shanghai, China. The Chinese company provides financial investment services.

Part of AffaMed Therapeutics, Affamed Therapeutics (US), Inc. is a clinical stage biopharmaceutical company based in New York, NY. The private company focuses on developing and commercializing pharmaceutical, digital, and surgical products to address critical unmet medical needs in ophthalmological, neurological, and psychiatric disorders for patients worldwide. The CEO of the company is Dayao Zhao.